Study on the relationship between 5-HTT gene polymorphism and the efficacy and safety of dapoxetine in the treatment of premature ejaculation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042898

Enrollment

Unknown

Registered

2021-01-31

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation

Interventions

Case group:Dapoxetine

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. male patient aged 18-64 years; 2. in a heterosexual, stable, and monogamous sexual relationship with the same female partner for >6 months, 3. possible sexual attempts of once a week or more; 4. with an International Index of Erectile Function-5 (IIEF-5) score >= 22, indicating normal erectile function.

Exclusion criteria

Exclusion criteria: 1. with any concomitant diseases, such as hyperthyroidism, diabetes, heart diseasehyperthyroidism,etc. 2. with other urinary diseasessuch as prostatic inflammation, urinary system infection,etc. 3. with a history of psychological diseases

Design outcomes

Primary

Measure	Time frame
IELT;Patient-reported outcomes (PROs);adverse effects;Polymorphisms;	—

Countries

China

Contacts

Public ContactZhang Xiansheng

The First Affiliated Hospital of Anhui Medical University

xiansheng-zhang@163.com+86 13514971898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026